Anxiogenic Effect of Cholecystokinin in the Dorsal Periaqueductal Gray

被引:0
|
作者
Cristina Ferreira Netto
Francisco Silveira Guimarães
机构
[1] Laboratory of Psychobiology,Department of Pharmacology
[2] FFCLRP,undefined
[3] FMRP,undefined
来源
Neuropsychopharmacology | 2004年 / 29卷
关键词
elevated plus-maze; CCK receptors; anxiety; Fos;
D O I
暂无
中图分类号
学科分类号
摘要
Systemic administration of cholecystokinin (CCK) fragments produces anxiogenic effects. The dorsal periaqueductal gray (dPAG) has been related to anxiety and panic reactions. The objective of this study was to investigate a possible anxiogenic effect of CCK-8 microinjected into the dPAG. At 10 min after the last microinjection (0.5 μl) into the dPAG male Wistar rats (N=7–17) were tested in the elevated plus-maze, an animal model of anxiety. The following treatments were tested alone or in combination: sulfated CCK-8 (CCK-8s, 0.5–1 μg), PD 135,158 (N-methyl-D-glucamine, 0.1 μg), a CCK-2 receptor antagonist, lorglumide (0.1–0.3 μg), a CCK-1 receptor antagonist. In addition, Fos immunohistochemistry was performed in rats (n=3–4) treated with CCK-8s (1 μg) alone or in combination with PD 135,158 (0.1 μg). CCK-8s produced anxiogenic-like effect, decreasing the percentage of time spent in open arm (saline=30.3±6.6, CCK 0.5 μg=15.2±1.8; CCK 1 μg=14.6±2.1). This effect was prevented by pretreatment with PD 135,158, but not by lorglumide. CCK-8s injected into the dPAG induced Fos immunoreactivity in several brain areas related to defensive behavior, including the PAG, median, and dorsal raphe nuclei, superior colliculus, lateral septal nuclei, medial hypothalamus, and medial amygdala. This effect was also prevented by pretreatment with PD 135,158. These results suggest that CCK-8s, acting on CCK-2 receptors, may modulate anxiety reactions in the dPAG.
引用
收藏
页码:101 / 107
页数:6
相关论文
共 50 条
  • [1] Anxiogenic effect of cholecystokinin in the dorsal periaqueductal gray
    Netto, CF
    Guimaraes, FS
    NEUROPSYCHOPHARMACOLOGY, 2004, 29 (01) : 101 - 107
  • [2] Anxiogenic effect of corticotropin-releasing hormone in the dorsal periaqueductal grey
    Martins, AP
    Marras, RA
    Guimaraes, FS
    NEUROREPORT, 1997, 8 (16) : 3601 - 3604
  • [3] ANXIOGENIC-LIKE EFFECT OF GLYCINE AND D-SERINE MICROINJECTED INTO DORSAL PERIAQUEDUCTAL GRAY-MATTER OF RATS
    SCHMITT, ML
    COELHO, W
    LOPESDESOUZA, AS
    GUIMARAES, FS
    CAROBREZ, AP
    NEUROSCIENCE LETTERS, 1995, 189 (02) : 93 - 96
  • [4] Anxiogenic-like effect induced by TRPV1 receptor activation within the dorsal periaqueductal gray matter in mice
    Mascarenhas, Diego Cardozo
    Gomes, Karina Santos
    Nunes-de-Souza, Ricardo Luiz
    BEHAVIOURAL BRAIN RESEARCH, 2013, 250 : 308 - 315
  • [5] Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray
    Martins, AP
    Marras, RA
    Guimaraes, FS
    DEPRESSION AND ANXIETY, 2000, 12 (02) : 99 - 101
  • [6] Anxiolytic effect of methylene blue microinjected into the dorsal periaqueductal gray matter
    de-Oliveira, RW
    Guimaraes, FS
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1999, 32 (12) : 1529 - 1532
  • [7] ANXIOLYTIC EFFECT OF MIDAZOLAM MICROINJECTED INTO THE DORSAL PERIAQUEDUCTAL GRAY AREA OF RATS
    RUSSO, AS
    GUIMARAES, FS
    DEAGUIAR, JC
    GRAEFF, FG
    BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, 1991, 24 (06) : 607 - 609
  • [8] Opposite effects of substance P fragments C (anxiogenic) and N (anxiolytic) injected into dorsal periaqueductal gray
    De Araújo, JE
    Huston, JP
    Brandao, ML
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 432 (01) : 43 - 51
  • [9] Anxiolytic-like effect of noradrenaline microinjection into the dorsal periaqueductal gray of rats
    Pelosi, Gislaine G.
    Resstel, Leonardo L. B. M.
    Soares, Vanessa R.
    Zangrossi, Helio
    Guimaraes, Francisco S.
    Correa, Fernando M. A.
    BEHAVIOURAL PHARMACOLOGY, 2009, 20 (03): : 252 - 259
  • [10] ANXIOLYTIC EFFECT OF GLYCINE ANTAGONISTS MICROINJECTED INTO THE DORSAL PERIAQUEDUCTAL GRAY
    MATHEUS, MG
    NOGUEIRA, RL
    CAROBREZ, AP
    GRAEFF, FG
    GUIMARAES, FS
    PSYCHOPHARMACOLOGY, 1994, 113 (3-4) : 565 - 569